Research graph
References from The value of community engagement in the ESTRO–EORTC OligoCare project: A quantification of the in-kind contributions. Local targets link to admitted publications; unresolved targets remain external evidence.
Recent developments in radiotherapy
10.1056/nejmra1608986 · 2017 · External reference
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium
10.1016/s1470-2045(22)00752-5 · 2023 · External reference
What will radiation oncology look like in 2050? A look at a changing professional landscape in Europe and beyond
10.1002/1878-0261.12731 · 2020 · External reference
An international modified Delphi study to prioritise levels of evidence and outcomes to appraise radiotherapy innovation in the ESTRO value-based radiation oncology framework
10.1016/s1470-2045(25)00732-6 · 2026 · External reference
Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC–ESTRO OligoCare consortium
10.1016/s1470-2045(26)00075-6 · 2026 · External reference
Assessing the gold standard--lessons from the history of RCTs
10.1056/nejmms1604593 · 2016 · External reference
Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective
10.1016/s1470-2045(18)30917-3 · 2019 · External reference
Real-world evidence - what is it and what can it tell us?
10.1056/nejmsb1609216 · 2016 · External reference
Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: an interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study
10.1016/j.radonc.2024.110235 · 2024 · External reference
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European organisation for research and treatment of Cancer consensus recommendation
10.1016/s1470-2045(19)30718-1 · 2020 · External reference
Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: real-world data from the E2-RADIatE OligoCare cohort
2024 · External reference
Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: an interim analysis of the E2-RADIatE OligoCare cohort
10.1016/j.radonc.2024.110466 · 2024 · External reference
Cost evaluation to optimise radiation therapy implementation in different income settings: a time-driven activity-based analysis
10.1016/j.radonc.2017.08.021 · 2017 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
External reference
European Groundshot-addressing Europe’s cancer research challenges: a lancet oncology commission
10.1016/s1470-2045(22)00540-x · 2023 · External reference
Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments
10.1016/s1470-2045(23)00182-1 · 2023 · External reference
Costs of drug development and Research and Development intensity in the US, 2000-2018
10.1001/jamanetworkopen.2024.15445 · 2024 · External reference
Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey
10.1016/j.radonc.2014.08.034 · 2014 · External reference
